JP2003512036A - Ｔａｄｇ−１５：癌において過剰発現されている細胞外セリンプロテアーゼ - Google Patents

Ｔａｄｇ−１５：癌において過剰発現されている細胞外セリンプロテアーゼ

Info

Publication number
JP2003512036A
JP2003512036A JP2001531854A JP2001531854A JP2003512036A JP 2003512036 A JP2003512036 A JP 2003512036A JP 2001531854 A JP2001531854 A JP 2001531854A JP 2001531854 A JP2001531854 A JP 2001531854A JP 2003512036 A JP2003512036 A JP 2003512036A
Authority
JP
Japan
Prior art keywords
tadg
protein
cancer
dna
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001531854A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003512036A5 (enExample
Inventor
ジェイ オブライアン，ティモシー
タニモト，ヒロトシ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arkansas at Little Rock
Original Assignee
University of Arkansas at Little Rock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/421,213 external-priority patent/US7022821B1/en
Application filed by University of Arkansas at Little Rock filed Critical University of Arkansas at Little Rock
Publication of JP2003512036A publication Critical patent/JP2003512036A/ja
Publication of JP2003512036A5 publication Critical patent/JP2003512036A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2001531854A 1999-10-20 2000-10-20 Ｔａｄｇ−１５：癌において過剰発現されている細胞外セリンプロテアーゼ Pending JP2003512036A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/421,213 1999-10-20
US09/421,213 US7022821B1 (en) 1998-02-20 1999-10-20 Antibody kit for the detection of TADG-15 protein
PCT/US2000/029095 WO2001029056A1 (en) 1999-10-20 2000-10-20 Tadg-15: an extracellular serine protease overexpressed in carcinomas

Publications (2)

Publication Number Publication Date
JP2003512036A true JP2003512036A (ja) 2003-04-02
JP2003512036A5 JP2003512036A5 (enExample) 2007-12-20

Family

ID=23669632

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001531854A Pending JP2003512036A (ja) 1999-10-20 2000-10-20 Ｔａｄｇ−１５：癌において過剰発現されている細胞外セリンプロテアーゼ

Country Status (6)

Country Link
EP (2) EP1226150A4 (enExample)
JP (1) JP2003512036A (enExample)
AU (1) AU774106B2 (enExample)
CA (1) CA2388450C (enExample)
MX (1) MXPA02004046A (enExample)
WO (1) WO2001029056A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007503817A (ja) * 2003-08-29 2007-03-01 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ アーカンソー 卵巣癌の早期診断方法
JP2010535506A (ja) * 2007-08-07 2010-11-25 オクフォルド ゲノメ スシエンセス （ユーケー） リミテッド マトリプターゼタンパク質及びその使用
JP2012211904A (ja) * 2006-06-06 2012-11-01 Oxford Genome Sciences (Uk) Ltd タンパク質

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157596B2 (en) 2000-09-08 2007-01-02 Dendreon Corporation Inhibitors of serine protease activity of matriptase or MTSP1
US7019019B2 (en) 2002-12-23 2006-03-28 Dendreon Corporation Matriptase inhibitors and methods of use
US7572444B2 (en) 2004-12-20 2009-08-11 Amgen Fremont Inc. Binding proteins specific for human matriptase
WO2010129609A2 (en) 2009-05-07 2010-11-11 The Regents Of The University Of California Antibodies and methods of use thereof
US8455200B2 (en) 2009-10-15 2013-06-04 Traxxsson, Llc Measurement of PKA for cancer detection
AU2011299088B2 (en) 2010-09-09 2015-12-24 Traxxsson, Llc Combination methods of diagnosing cancer in a patient
US9255155B2 (en) 2013-01-31 2016-02-09 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of treating cancer
MX2016006486A (es) 2013-11-25 2016-08-05 Oxford Biotherapeutics Ltd Anticuerpos.
US9272027B1 (en) 2014-09-08 2016-03-01 The United States Of America As Represented By The Secretary Of The Air Force Francisella tularensis live vaccine strains and methods of use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09149790A (ja) * 1995-09-29 1997-06-10 Suntory Ltd 新規セリンプロテアーゼ
WO1998041656A1 (en) * 1997-03-19 1998-09-24 The Board Of Trustees Of The University Of Arkansas Compositions and method for the early diagnosis of ovarian cancer
WO1999036550A2 (en) * 1998-01-16 1999-07-22 Incyte Pharmaceuticals, Inc. Human protease molecules
WO1999042120A1 (en) * 1998-02-20 1999-08-26 The Board Of Trustees Of The University Of Arkansas Tadg-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas
JP2002539093A (ja) * 1999-03-12 2002-11-19 ジョージタウン ユニバーシティ マトリプターゼ、セリンプロテアーゼおよびその応用
JP2003532372A (ja) * 1999-01-11 2003-11-05 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒトペプチダーゼ

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09149790A (ja) * 1995-09-29 1997-06-10 Suntory Ltd 新規セリンプロテアーゼ
WO1998041656A1 (en) * 1997-03-19 1998-09-24 The Board Of Trustees Of The University Of Arkansas Compositions and method for the early diagnosis of ovarian cancer
WO1999036550A2 (en) * 1998-01-16 1999-07-22 Incyte Pharmaceuticals, Inc. Human protease molecules
WO1999042120A1 (en) * 1998-02-20 1999-08-26 The Board Of Trustees Of The University Of Arkansas Tadg-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas
JP2003532372A (ja) * 1999-01-11 2003-11-05 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒトペプチダーゼ
JP2002539093A (ja) * 1999-03-12 2002-11-19 ジョージタウン ユニバーシティ マトリプターゼ、セリンプロテアーゼおよびその応用

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007503817A (ja) * 2003-08-29 2007-03-01 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ アーカンソー 卵巣癌の早期診断方法
JP2012211904A (ja) * 2006-06-06 2012-11-01 Oxford Genome Sciences (Uk) Ltd タンパク質
JP2010535506A (ja) * 2007-08-07 2010-11-25 オクフォルド ゲノメ スシエンセス （ユーケー） リミテッド マトリプターゼタンパク質及びその使用

Also Published As

Publication number Publication date
EP1887082A3 (en) 2008-06-11
AU1221501A (en) 2001-04-30
MXPA02004046A (es) 2002-10-11
AU774106B2 (en) 2004-06-17
EP1226150A4 (en) 2005-05-25
EP1887082A2 (en) 2008-02-13
EP1226150A1 (en) 2002-07-31
WO2001029056A1 (en) 2001-04-26
CA2388450C (en) 2013-02-12
CA2388450A1 (en) 2001-04-26

Similar Documents

Publication Publication Date Title
US7939321B2 (en) TADG-15: an extracellular serine protease overexpressed in carcinomas
JP4558948B2 (ja) 卵巣癌において過剰発現される膜貫通型セリンプロテアーゼおよびその使用
US7067630B2 (en) Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof
US7306927B2 (en) Method of inducing immunity against stratum corneum chymotrytic enzyme
JP2003523524A5 (enExample)
US8609819B2 (en) Extracellular serine protease
EP1887082A2 (en) TADG-15: An extracellular serine protease overexpressed in carcinomas
JP4253120B2 (ja) 新規な細胞外セリンプロテアーゼ
US7759103B2 (en) Extracellular serine protease
US7157084B2 (en) Extracellular serine protease
US6642013B1 (en) Extracellular serine protease
AU2001234910A1 (en) Compositions and methods for the early diagnosis of ovarian cancer

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101013

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110113

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110208